The highlight of this study is that the survival rate of TP53 WT GC patients is significantly lower than that of TP53 mut GC patients, suggesting that clinically, patients with gastric cancer have worse prognosis if they do not have TP53 mutation and that wild type TP53 is an indicator of poor prognosis in GC patients. Here, TP53 is linked to gastric cancer.